Pioneering method of treating Alzheimer’s discredited by scientists
Bexarotene, sold under the name Targretin, had caused ripples of excitement across the medical profession
A drug hailed as a pioneering method of treating Alzheimer’s has been discredited by scientists, after experts were unable to replicate its results this week.
Bexarotene, sold under the name Targretin, had caused ripples of excitement across the medical profession, following high profile research that suggested it could be used to treat the symptoms of Alzheimer’s.
The 2012 research, produced by Gary Landreth and colleagues at Case Western Reserve University in Cleveland and published in Science journal, reported that the drug appeared to reduce the brain plaque build-ups linked to the disease when administered to mice.
Once the results of the study were made public, patients began requesting the drug and some doctors reportedly began prescribing it.
However, a team of experts have now written in the same journal that they have been unable to re-create the results found in the original survey, plunging its validity into doubt.
Sangram Sisodia, professor of neuroscience at the University of Chicago, decided to investigate claims made that the drug could reduce the areas of plaque by 50 per cent within three days, and by 75 per cent in two weeks.
In his replica study published on Thursday, he said: “In view of the significant implications of these landmark findings for the development of novel AD therapeutics, we performed a small pilot study […] using 8-month-old male APP/PS1 mice that were treated orally with a commercial source of bexarotene for seven days.”
Crucially, he said: “We failed to observe any differences in hippocampal or cortical amyloid plaque area or plaque counts between vehicle and bexarotene-treated animals.”
Bexarotene was approved by the FDA in 1999 as a treatment for skin cancer, but has never before been tested as a treatment for humans with Alzheimer’s. Because it has been approved by the FDA it can be prescribed by physicians for use ‘off label.’
However, some scientists argued that whilst the effects on brain plaque had not been replicated, the cognitive improvements had.
Writing in Science, Professor Koldamova said: “We believe these findings make a solid case for continued exploration of bexarotene as a therapeutic treatment for Alzheimer's disease.”
The party's potential nominations read like a high school race for student body president
- 1 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Mia Khalifa: Pornhub star claims Drake sent her 'cringeworthy' naked photos on Instagram
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
£33000 per annum: Recruitment Genius: An External Relations Executive is requi...
£25000 - £28000 per annum + 25 days holidays & pension: Ashdown Group: Web Dev...
£7 - £9 per hour: Recruitment Genius: An exciting opportunity has arisen to jo...
£45000 - £50000 per annum + Benefits: Ashdown Group: Marketing Manager (Market...